Abstract
Objectives: Botulinum toxin type A is a potent neuromuscular paralyzing agent used in various disorders including cervical dystonia. Two preparations of botulinum toxin are now commercially available ( Dysport and Botox), but much controversy remains about their respective potencies. The aim of the study was to compare the efficacy of Botox with two different ratios of Dysport.
Methods: A double blind, randomised, three period cross over study involving 54 patients with cervical dystonia was performed. The patients received the following treatments in a randomised order: Botox at the usually effective dose, Dysport at a dose of 1:3 (conversion factor of 3 between Botox and Dysport units—that is, one Botox unit=three Dysport units) and at a dose of 1:4 (conversion factor of four). The improvement of the Tsui (primary outcome criteria) and of the TWSTRS pain scales between baseline and a control visit 1 month after each of the three injections, as well as the incidence of adverse events, were assessed.
Results: Comparison of the Tsui scores and of the TWSTRS pain scores showed a better effect on impairment and pain with Dysport 1:3 (p=0.02 and 0.04, respectively) and 1:4 (p=0.01 and 0.02, respectively) than with Botox. The number of adverse events was higher with both Dysport treatments. The most frequent adverse event was dysphagia, found in 3%, 15.6%, and 17.3% (Botox, Dysport 1:3 and 1:4, respectively) of the patients. No adverse event required withdrawal of therapy or specific management.
Conclusions: Dysport 1:3 (and Dysport 1:4 to a greater extent) is more efficient than Botox for both impairment and pain in cervical dystonia although with a somewhat higher incidence of minor adverse effects. This strongly suggests that the most appropriate conversion factor between Botox and Dysport units is less than 3 in cervical dystonia.
Full Text
The Full Text of this article is available as a PDF (100.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borodic G. E., Pearce L. B., Smith K., Joseph M. Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck. 1992 Jan-Feb;14(1):33–37. doi: 10.1002/hed.2880140108. [DOI] [PubMed] [Google Scholar]
- Borodic G. Therapeutic botulinum toxin. Lancet. 1994 Nov 12;344(8933):1370–1370. doi: 10.1016/s0140-6736(94)90732-3. [DOI] [PubMed] [Google Scholar]
- Brin M. F., Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med. 1993 Aug;86(8):493–494. [PMC free article] [PubMed] [Google Scholar]
- Eleopra R., Tugnoli V., De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord. 1997 Jan;12(1):89–94. doi: 10.1002/mds.870120115. [DOI] [PubMed] [Google Scholar]
- Gelb D. J., Lowenstein D. H., Aminoff M. J. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology. 1989 Jan;39(1):80–84. doi: 10.1212/wnl.39.1.80. [DOI] [PubMed] [Google Scholar]
- Jankovic J., Brin M. F. Therapeutic uses of botulinum toxin. N Engl J Med. 1991 Apr 25;324(17):1186–1194. doi: 10.1056/NEJM199104253241707. [DOI] [PubMed] [Google Scholar]
- Krack P., Deuschl G., Benecke R., Ceballos-Baumann A. O., Marion M. H., Oertel W. H., Poewe W. Dose standardization of botulinum toxin. Mov Disord. 1998 Jul;13(4):749–751. doi: 10.1002/mds.870130425. [DOI] [PubMed] [Google Scholar]
- Marion M. H., Sheehy M., Sangla S., Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):102–103. doi: 10.1136/jnnp.59.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Odergren T., Hjaltason H., Kaakkola S., Solders G., Hanko J., Fehling C., Marttila R. J., Lundh H., Gedin S., Westergren I. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6–12. doi: 10.1136/jnnp.64.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., Kessler K. R., Ceballos-Baumann A. O., Ohly A., Oertel W. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13–17. doi: 10.1136/jnnp.64.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sampaio C., Ferreira J. J., Simões F., Rosas M. J., Magalhães M., Correia A. P., Bastos-Lima A., Martins R., Castro-Caldas A. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord. 1997 Nov;12(6):1013–1018. doi: 10.1002/mds.870120627. [DOI] [PubMed] [Google Scholar]
- Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord. 1997 Jan;12(1):100–102. doi: 10.1002/mds.870120117. [DOI] [PubMed] [Google Scholar]
- Tsui J. K., Eisen A., Stoessl A. J., Calne S., Calne D. B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986 Aug 2;2(8501):245–247. doi: 10.1016/s0140-6736(86)92070-2. [DOI] [PubMed] [Google Scholar]
- Wohlfarth K., Göschel H., Frevert J., Dengler R., Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):335–340. doi: 10.1007/pl00004951. [DOI] [PubMed] [Google Scholar]